These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 3045266)

  • 1. High-dose combination alkylating agent therapy with autologous bone marrow rescue for refractory solid tumors.
    Slease RB; Benear JB; Selby GB; Reitz CL; Hughes WL; Watkins CL; Epstein RB
    J Clin Oncol; 1988 Aug; 6(8):1314-20. PubMed ID: 3045266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose combination alkylating agent preparative regimen with autologous bone marrow support: the Dana-Farber Cancer Institute/Beth Israel Hospital experience.
    Antman K; Eder JP; Elias A; Shea T; Peters WP; Andersen J; Schryber S; Henner WD; Finberg R; Wilmore D
    Cancer Treat Rep; 1987 Feb; 71(2):119-25. PubMed ID: 3542208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study.
    Wheeler C; Antin JH; Churchill WH; Come SE; Smith BR; Bubley GJ; Rosenthal DS; Rappaport JM; Ault KA; Schnipper LE
    J Clin Oncol; 1990 Apr; 8(4):648-56. PubMed ID: 2313334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carmustine, Ara C, cyclophosphamide and etoposide with autologous bone marrow transplantation in relapsed or refractory lymphoma: a dose-finding study.
    Snyder MJ; Johnson DB; Daly MB; Giguere JK; Harman GH; Harden EA; Johnson RA; Leff RS; Mercier RJ; Messerschmidt GL
    Bone Marrow Transplant; 1994 Oct; 14(4):595-600. PubMed ID: 7858534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of repeated cycles of high-dose cyclophosphamide, etoposide, and cisplatin administered without bone marrow transplantation.
    Neidhart JA; Kohler W; Stidley C; Mangalik A; Plauche A; Anderson T; Quenzer RW; Rinehart JJ
    J Clin Oncol; 1990 Oct; 8(10):1728-38. PubMed ID: 2213108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose chemotherapy with BEAC regimen and autologous bone marrow transplantation for intermediate grade and immunoblastic lymphoma: durable complete remissions, but a high rate of regimen-related toxicity.
    van Besien K; Tabocoff J; Rodriguez M; Andersson B; Mehra R; Przepiorka D; Dimopoulos M; Giralt S; Suki S; Khouri I
    Bone Marrow Transplant; 1995 Apr; 15(4):549-55. PubMed ID: 7655380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancer.
    Eder JP; Antman K; Peters W; Henner WD; Elias A; Shea T; Schryber S; Andersen J; Come S; Schnipper L
    J Clin Oncol; 1986 Nov; 4(11):1592-7. PubMed ID: 3534155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I/II study incorporating intravenous hydroxyurea into high-dose chemotherapy for patients with primary refractory or relapsed and refractory intermediate-grade and high-grade malignant lymphoma.
    Vaughan WP; Kris E; Vose J; Bierman PJ; Gwilt P; Armitage JO
    J Clin Oncol; 1995 May; 13(5):1089-95. PubMed ID: 7738614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Escalating dose of mitoxantrone with high-dose cyclophosphamide, carmustine, and etoposide in patients with refractory lymphoma undergoing autologous bone marrow transplantation.
    Attal M; Canal P; Schlaifer D; Chatelut E; Dezeuze A; Huguet F; Payen C; Pris J; Laurent G
    J Clin Oncol; 1994 Jan; 12(1):141-8. PubMed ID: 8270970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease.
    Jagannath S; Armitage JO; Dicke KA; Tucker SL; Velasquez WS; Smith K; Vaughan WP; Kessinger A; Horwitz LJ; Hagemeister FB
    J Clin Oncol; 1989 Feb; 7(2):179-85. PubMed ID: 2644397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose busulfan and cyclophosphamide followed by autologous transplantation in patients with advanced breast cancer.
    Demirer T; Buckner CD; Appelbaum FR; Clift R; Storb R; Myerson D; Lilleby K; Rowley S; Bensinger WI
    Bone Marrow Transplant; 1996 May; 17(5):769-74. PubMed ID: 8733696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose, potentially myeloablative chemotherapy and autologous bone marrow transplantation for patients with advanced Hodgkin's disease.
    Ahmed T; Ciavarella D; Feldman E; Ascensao J; Hussain F; Engelking C; Gingrich S; Mittelman A; Coleman M; Arlin ZA
    Leukemia; 1989 Jan; 3(1):19-22. PubMed ID: 2642573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I trial of dacarbazine with cyclophosphamide, carmustine, etoposide, and autologous stem-cell transplantation in patients with lymphoma and multiple myeloma.
    Adkins DR; Salzman D; Boldt D; Kuhn J; Irvin R; Roodman GD; Lyons R; Smith L; Freytes CO; LeMaistre CF
    J Clin Oncol; 1994 Sep; 12(9):1890-901. PubMed ID: 7916039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized trial of high-dose chemotherapy with autologous bone marrow support as adjuvant therapy for high-risk, multi-node-positive malignant melanoma.
    Meisenberg BR; Ross M; Vredenburgh JJ; Jones R; Shpall EJ; Seigler HF; Coniglio DM; Wu K; Peters WP
    J Natl Cancer Inst; 1993 Jul; 85(13):1080-5. PubMed ID: 8515495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclophosphamide/mitoxantrone/melphalan (CMA) regimen prior to autologous bone marrow transplantation (ABMT) in metastatic breast cancer.
    Gisselbrecht C; Extra JM; Lotz JP; Devaux Y; Janvier M; Peny AM; Guillevin L; Bremond D; Delain M; Herbrecht R; Lepage E; Maraninchi D
    Bone Marrow Transplant; 1996 Nov; 18(5):857-63. PubMed ID: 8932837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intensive 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), NSC #4366650 and cryopreserved autologous marrow transplantation for refractory cancer. A phase I-II study.
    Phillips GL; Fay JW; Herzig GP; Herzig RH; Weiner RS; Wolff SN; Lazarus HM; Karanes C; Ross WE; Kramer BS
    Cancer; 1983 Nov; 52(10):1792-802. PubMed ID: 6354414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose combination alkylating agents with autologous bone marrow support: a Phase 1 trial.
    Peters WP; Eder JP; Henner WD; Schryber S; Wilmore D; Finberg R; Schoenfeld D; Bast R; Gargone B; Antman K
    J Clin Oncol; 1986 May; 4(5):646-54. PubMed ID: 3517240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The European experience with megadose therapy and autologous bone marrow transplantation in solid tumors with poor prognosis Ewing sarcoma, germ cell tumors and brain tumors)].
    Ladenstein R; Gadner H; Hartmann O; Pico J; Biron P; Thierry P
    Wien Med Wochenschr; 1995; 145(2-3):55-7. PubMed ID: 7762255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation in patients with lymphoid malignancies who have received dose-limiting radiation therapy.
    Weaver CH; Appelbaum FR; Petersen FB; Clift R; Singer J; Press O; Bensinger W; Bianco J; Martin P; Anasetti C
    J Clin Oncol; 1993 Jul; 11(7):1329-35. PubMed ID: 8315430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer.
    Peters WP; Shpall EJ; Jones RB; Olsen GA; Bast RC; Gockerman JP; Moore JO
    J Clin Oncol; 1988 Sep; 6(9):1368-76. PubMed ID: 3047332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.